Standard Biotools Q3 FY24: revenue $45.5M; diluted EPS −$0.27
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-057213
- Document
- 10-Q
Key figures from this report
These are the numbers Standard Biotools reported for Q3 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$45.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$32.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$0.27No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$287.1MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$62.5MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Aquestive Therapeutics AQST public float $292M, Jun 30, 2025
- Siga Technologies SIGA public float $302M, Jun 30, 2025
- Ocugen OCGN public float $279M, Jun 30, 2025
- Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
- Tonix Pharmaceuticals Holding TNXP public float $271M, Jun 30, 2025